India, Aug. 11 -- IMUNON, Inc. (IMNN), a clinical-stage biotechnology company developing DNA-mediated immunotherapies, reported its second-quarter 2026 financial results and provided a business update, with investors focusing on continued progress in the pivotal Phase 3 OVATION 3 trial of IMNN-001 in newly diagnosed advanced ovarian cancer.
IMNN-001 is an investigational DNA-based immunotherapy designed to deliver interleukin-12 (IL-12) locally at the tumor site, stimulating cancer-fighting immune responses.
The company said enrollment in the OVATION 3 Phase 3 trial is progressing faster than expected, supported by positive Phase 2 OVATION 2 results showing a 14.7-month improvement in median overall survival, at 45.1 months compared with ...